Treatment Affordability

Inspired by a real patient.

ELIGARD® is one of the most affordable ADTs

ELIGARD has not had a price increase for over 10 years2†

Tolmar understands that cancer can bring financial stress along with emotional and physical challenges and is dedicated to making affordable treatment. With ELIGARD, you can feel more confident about the cost of treatment, which can help keep your out-of-pocket (OOP) burden as low as possible. 

*
Price refers to the Wholesale Acquisition Cost (WAC), standardized to a one-month supply. Actual out-of-pocket costs may vary based on insurance coverage and individual plan details.
ELIGARD has consistently had one of the lowest prices in the gonadotropin-releasing hormone (GnRH) market, helping make care more affordable2†
†
The prices shown are based on the Wholesale Acquisition Cost (WAC) for a one-month supply. What you pay out-of-pocket will depend on your insurance plan and coverage.

†Prices shown are based on Wholesale Acquisition Cost (WAC) as of January 2026, standardized to a one-month supply. WAC is the price a manufacturer charges wholesalers before products are dispensed to patients. Actual out-of-pocket costs may vary based on insurance coverage, benefits design, and individual plan details.

Understand financial toxicity and how to ease the burden of care

LEARN MORE

Medicare Part D changed in 2026, potentially affecting costs for patients 

If you take oral cancer medications, you may face high out-of-pocket (OOP) costs. These treatments often come with significant co-pays or coinsurance—especially if your insurance plan uses a tiered prescription system.

While Medicare Part D now caps annual OOP costs at $2,100, you may still see higher monthly out-of-pocket costs depending on when treatment begins. You may also choose to spread these costs out over time through the Medicare Prescription Payment Plan, which can help with budgeting but does not reduce the total amount owed.3,10
Talk to your doctor about an ADT option that offers long-standing efficacy and stable pricing—ELIGARD is the market-leading therapy with over 20 years of proven results and has not increased its price in the last decade.

How rising cancer costs & inflation are affecting your care

You shouldn’t have to compromise your financial well-being for quality healthcare  

Cancer is one of the most expensive medical conditions to treat in the United States and continues to be a growing financial burden. It can be difficult to manage the cost of cancer care while also covering essentials like housing, utilities, transportation, and food.4

As inflation pushes prices higher, ELIGARD holds steady2,7

When cancer care costs rise, you may face high out-of-pocket expenses that make it harder to keep up with treatments or medications.6
98
MILLION AMERICANS
skipped treatment or cut spending on essentials to cover health care costs8

64%

of cancer patients experience increased stress from medical debts and out-of-pocket costs9

You may be able to avoid the financial stress caused by treatment by considering a low-cost ADT like ELIGARD 

Financial assistance

You may be nervous about the financial aspects of being diagnosed with cancer, but there are many organizations dedicated to helping you with those costs. Speak with the organizations below to see what type of assistance they may be able to offer. You should also check with your doctor’s office to see if other assistance is available.

This list is provided for informational purposes only and does not indicate an endorsement or sponsorship.

BenefitsCheckUp®​

BenefitsCheckup.org

CFAC: Cancer Financial Assistance Coalition

CancerFAC.org

CancerCare® Co-Payment Assistance Foundation

CancerCareCoPay.org​ 1-866-55-COPAY (2-6729)

HealthWell Foundation®​

HealthWellFoundation.org 1-800-675-8416

Medicine Assistance Tool

MedicineAssistanceTool.org

Patient Advocate Foundation

Copays.org
1-866-512-3861

Financial toxicity

Tolmar is dedicated to making affordable treatment with ELIGARD® a reality for prostate cancer patients. Many patients with cancer face some degree of financial hardship and illness-related money troubles. With ELIGARD, patients can feel confident in the affordability of treatment and that cost burden is kept as low as possible.

  • Consistently has been one of the lowest wholesale acquisition costs (WACs) in the GnRH market
  • No WAC increase in more than 10 years1

*The market-leading luteinizing hormone-releasing hormone (LHRH) agonist.

Understand financial toxicity and how to ease the burden of care

LEARN MORE

Explore additional support resources

Get More Support
ADT, androgen deprivation therapy; OOP, out-of-pocket; WAC, wholesale acquisition cost.

References: 1. Data on file. Tolmar, Inc.; 2026. 2. Data on file. Tolmar, Inc.; 2026. 3. KFF. 2020 Employer Health Benefits Survey. Accessed November 2024. https://www.kff.org/report-section/ehbs-2020-section-9-prescription-drug-benefits 4. National Institutes of Health. National Cancer Institute. Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version. Updated June 6, 2024. Accessed April 1, 2025. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-pdq 5. Mariotto A, Enewold L, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304-1312. 6. Yabroff KR, et al. Cancer diagnosis and treatment in working-age adults: Implications for employment, health insurance coverage, and financial hardship in the United States. AC: Can Jrnl Clin. 2024;74(4)341-358. 7. Davidenko V, Sweitzer M. U.S. food prices rose by 23.6 percent from 2020 to 2024. USDA Economic Research Service. Published February 14, 2025. Accessed April 30, 2025. https://www.ers.usda.gov/data-products/chart-gallery/chart-detail?chartId=58350# 8. WestHealth/Gallup. Estimated 98 million Americans skipped treatments, cut back on food, gas or utilities to pay for healthcare. Published August 4, 2022. Accessed April 30, 2025. https://westhealth.org/news/estimated-98-million-americans-skipped-treatments-cut-back-on-food-gas-or-utilities-to-pay-for-healthcare/ 9. National Institutes of Health. National Cancer Institute. Financial Toxicity and Cancer Treatment (PDQ)-Health Professional Version. Updated May 29, 2024. Accessed April 30, 2025. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq 10. Formularies CVS Health. 2017 Drug Trend Report. Published 2017. Accessed May 21, 2025. https://s2.q4cdn.com/447711729/files/doc_downloads/company_documents/2017-drug-trend-report.pdf

Other links

You are now leaving ELIGARD.com.

Are you sure you want to leave? 

YES
NO

You are now navigating to the healthcare provider site.

Are you a healthcare provider?

YES
NO
Skip to content